CTLA4 and neoplasm: The reported findings revealed that OVs expressing PD-1 inhibitors synergistically acted with anti-CTLA-4 or anti-TIM-3 agents to potentiate the immune response in vivo and consequently achieve tumor control (20) (Figure 1A).